Share: Facebook Twitter LinkedIn
Activity Provided By:

i3 Health

Expert Guidance on New Advances in Renal Cell Carcinoma

Access Activity

Overview / Abstract:


Kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States (ACS, 2020). An estimated 73,750 new cases are reported annually and 14,830 people die of the disease. Renal cell carcinoma, which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Due to its often asymptomatic presentation, many patients have advanced disease at diagnosis, which is associated with poor outcomes. The 5-year survival rate for patients with regional RCC is only 70% and drops to a dismal 12% for those with distant metastases (ACS, 2020).


Oncologists, urologists, oncology advanced practitioners, and other health care professionals involved in the treatment of patients with renal cell carcinoma (RCC).


Upon completion of this activity, participants should be able to:

1.) Assess recent clinical trial findings on first-line and second-line treatment of advanced RCC
2.) Tailor evidenced-based therapeutic strategies to individual patients with advanced RCC

This activity is also available as a podcast.


Nov 16, 2021


Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME


Online, Podcast, Webinar / Webcast / Video

Credits / Hours




Presenters / Authors / Faculty

Bradley McGregor, MD (Chairperson)
Clinical Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute

Robert Motzer, MD
Jack and Dorothy Byrne Chair in Clinical Oncology
Memorial Sloan Kettering Cancer Center

Activity Specialities / Related Topics

Adverse Drug Reactions / ADR, Education / Teaching, Medication Safety, Nephrology, Oncology / Cancer / Radiation Therapy, Urology

Sponsors / Supporters / Grant Providers

This educational activity is supported by a medical education grant from Exelixis, Inc. and an independent educational grant from Merck.

Keywords / Search Terms

i3 Health oncology, urology, renal cell carcinoma, RCC, kidney cancer, genitourinary cancers, CME, CNE, NCPD, ILNA points, MOC, free CME, free CNE, free NCPD, free ILNA points, i3 Health Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map